Dataset Information

Transcriptomic and proteomic analysis of human brain tissue from epileptic and non-epileptic groups

ABSTRACT: Abstract Objective: Epilepsy is a prevalent neurological disorder marked by seizures due to abnormal brain neuron discharge. Its pathological mechanism remains incompletely understood. This study utilizes transcriptomic and proteomic analyses on epileptic lesions from patients and brain tissue from non-epileptic individuals. The goal is to delve deeper into the molecular expression characteristics in the brain tissue of epilepsy patients, aiming to uncover potential biomarkers and therapeutic targets for epilepsy. Methods: Brain tissues from epileptic lesions post-surgical resection in epilepsy patients and brain tissues from non-epileptic patients were collected. RNA-seq transcriptomic analysis and isobaric Tags for Relative and Absolute Quantitation (iTRAQ) proteomic analysis were performed, followed by a combined analysis of transcriptomic and proteomic data. Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR), Western Blot (WB) and immunohistochemical staining (IHC) techniques were used to verify the expression levels of differentially expressed genes (DEGs) and differentially expressed proteins (DEPs). Results: Transcriptomic analysis identified 1604 differentially expressed genes, with 584 up-regulated and 1020 down-regulated. Proteomic analysis identified 694 differentially expressed proteins, with 331 up-regulated and 363 down-regulated. Combined transcriptomic and proteomic analyses showed that differential genes/proteins were mainly enriched in biological processes such as D-aspartate transport, transmembrane transport, cell junctions, vesicle transport, and metabolic processes. Tubulin Polymerization Promoting Protein Family Member 3 (TPPP3), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), and Dihydropyrimidinase-Like 3 (DPYSL3) were significantly altered in epilepsy patients, and their expression trends were confirmed by RT-qPCR, WB and IHC aligning with the transcriptomics and proteomics data. Significance: By integrating transcriptomic and proteomic analyses, this study identified differential genes/proteins between epileptic and non-epileptic patients and their associated biological processes. Three key differential genes/proteins, TPPP3, PCSK1, and DPYSL3, were highlighted, indicating their potential significance in the pathological mechanisms of epilepsy.

ORGANISM(S): Homo Sapiens

SUBMITTER: Hua Fang

PROVIDER: PXD054520 | iProX | Thu Aug 01 00:00:00 BST 2024

REPOSITORIES: iProX

ACCESS DATA

Publications

A transcriptomic and proteomic analysis and comparison of human brain tissue from patients with and without epilepsy.

Zhu Taiyang T Zhou Yan Y Zhang Lei L Kong Lingwen L Tang Hai H Xiao Qihua Q Sun Xiaoyu X Shen Fanyu F Zhou Hui H Ni Wanyan W Liu Sha S Gao Huimin H Jin Guoliang G Jia Xiao X Hua Fang F

Scientific reports 20250511 1

The present study was to investigate potential biomarkers and therapeutic targets for epilepsy by conducting a transcriptomic and proteomic analysis of human brain tissue from patients with epileptic lesions. Brain tissue was collected from the epileptic lesions after surgical resection and surgical removed brain tissue from non-epileptic patients. Using RNA sequencing and iTRAQ-based proteomic analysis, The transcriptomic analysis identified 1,604 DEGs, with 584 upregulated and 1,020 downregula ...[more]

PMID: 40350490

Similar Datasets

Project description:<h4><strong>INTRODUCTION: </strong>Approximately 1% of the world's population is impacted by epilepsy, a chronic neurological disorder characterized by seizures. One-third of epileptic patients are resistant to AEDs, or have medically refractory epilepsy (MRE). One non-invasive treatment that exists for MRE includes the ketogenic diet, a high-fat, low-carbohydrate diet. Despite the KD's success in seizure attenuation, it has a few risks and its mechanisms remain poorly understood. The KD has been shown to improve metabolism and mitochondrial function in epileptic phenotypes. Potassium channels have implications in epileptic conditions as they have dual roles as metabolic sensors and control neuronal excitation.</h4><h4><strong>OBJECTIVES: </strong>The goal of this study was to explore changes in the lipidome in hippocampal and cortical tissue from Kv1.1-KO model of epilepsy.</h4><h4><strong>METHODS: </strong>FT-ICR/MS analysis was utilized to examine nonpolar metabolome of cortical and hippocampal tissue isolated from a Kv1.1 channel knockout mouse model of epilepsy (n = 5) and wild-type mice (n = 5).</h4><h4><strong>RESULTS: </strong>Distinct metabolic profiles were observed, significant (p < 0.05) features in hippocampus often being upregulated (FC ≥ 2) and the cortex being downregulated (FC ≤ 0.5). Pathway enrichment analysis shows lipid biosynthesis was affected. Partition ratio analysis revealed that the ratio of most metabolites tended to be increased in Kv1.1-/-. Metabolites in hippocampal tissue were commonly upregulated, suggesting seizure initiation in the hippocampus. Aberrant mitochondrial function is implicated by the upregulation of cardiolipin, a common component in the mitochondrial membrane.</h4><h4><strong>CONCLUSION: </strong>Generally, our study finds that the lipidome is changed in the hippocampus and cortex in response to Kv1.1-KO indicating changes in membrane structural integrity and synaptic transmission.</h4>

Project description:Inherited mutations of calcium ion channels exhibit neurological defects, such as epilepsy, ataxia, and migraine, and these phenotypes are shared among humans and mouse models. Absence epilepsy and ataxic phenotypes are present in the calcium channelopathy mutants stargazer (stg-gamma2 subunit), tottering (tg-alpha1 subunit), and lethargic (lh-beta4 subunit). These mutations of high-voltage-activated (HVA) calcium channel subunits initiate increases in membrane excitability of low-voltage-activated (LVA) calcium channels in thalamic neurons, thus enhancing LVA currents. Elevated LVA currents, produced from T-type calcium channels, induce rhythmic thalamocortical burst firing and spike-wave seizures. The changes in gene expression originating from the different mutations result in similar T-type channel function; however, the network of gene modifications causing altered molecular plasticity and the emergence of pathological phenotypes remain unknown. We would like to understand how loss of 3 different subunits of a calcium ion channel differentially alter gene expression in the brain. Characterizing the gene expression profiles of the mutant stg, tg, and lh mice will provide evidence of the epileptic and ataxic mechanisms, which may identify potential therapeutic targets. We will compare the gene expression profiles among adult mutant stg, tg, and lh mice, which display the ataxic and epileptic phenotypes, along with their wildtype, litter-mate controls, in the cerebellum and brain (without cerebellum). We propose that the neuronal dysfunction associated with the ataxic and epileptic phenotypes develops from a common network of interacting gene alterations within the mutant stg, tg, and lh brain. The changes dictated by the initial mutations leading to the ataxic and epileptic phenotypes are hypothesized to be localized to the cerebellum and the remaining areas of the brain, including the thalamus and cortex, respectively. Adult mutant stg, tg, and lh mice, between 2 and 5 months of age, along with wildtype, litter-mate controls, will be sacrificed. Two brain regions responsible for two phenotypes will be examined. The cerebellum (ataxia) will be dissected from remainder of the forebrain (generalized epilepsy). Each tissue set will be collected in triplicate (3 separate mice per set) to account for biological variance, and total RNA isolated via standard Trizol procedure (Invitrogen) and purified with the RNeasy cleanup kit (Qiagen). RNA samples will be stored at -80 C until sent for analysis using the Affymetrix GeneChip Mouse Genome 430 2.0 whole genome array.

Project description:The ketogenic diet (KD) is an established treatment for patients with medically intractable epilepsy and is chiefly characterized by the production of ketone bodies (KB) such as β-hydroxybutyrate (BHB). However, after more than a century of clinical use, the mechanisms underlying its efficacy remain unclear. While prior investigations have examined the effects of the KD and its metabolic substrates on synaptic transmission, few studies have explored a potential connection between astrocytic ion channels and seizure genesis. One essential function of astrocytes is spatial potassium buffering which influences passive potassium conductance (PPC), and when impaired, can result in neuronal hyperexcitability. In the present study, we demonstrate that the KD can mitigate hippocampal astrogliosis in the Kcna1-null (KO) mouse model of developmental epilepsy. Specifically, we observed a significant increase in GFAP expression in KO mice fed a control diet compared to wild-type (WT) animals, and that the KD prevented this change. Furthermore, we noted a reduction in hippocampal astrocytic PPC in epileptic mice, whereas KD-treated KO animals exhibited nearly normal passive conductance levels. In this regard, we also provide evidence for the role of Kir4.1 channels in mediating astrocytic PPC, and the activation of these inwardly rectifying potassium channels by BHB. To further explore these findings at a molecular level, we conducted bulk RNA-seq analysis which revealed down-regulation of factors linked to hippocampal astrogliosis, notably those involved with neuroinflammation, consistent with earlier reports highlighting the anti-inflammatory effects of the KD and its metabolic substrates such as BHB. Our findings indicate that the KD protects against epilepsy-associated astrogliosis and astrocytic PPC changes, underscoring a novel mechanism of KD action, and the potential functional role of extracellular potassium in neuronal-glial interactions in the epileptic brain.

Project description:There are no blood-based molecular biomarkers of temporal lobe epilepsy (TLE) to support clinical diagnosis. MicroRNAs are short noncoding RNAs with strong biomarker potential due to their cell-specific expression, mechanistic links to brain excitability, and stable and reliable detection in biofluids. Altered expression of circulating microRNAs has been reported in human epilepsy, but most studies collected samples from one clinical site, relied on a single platform for profiling or conducted minimal validation. We collected plasma samples from video-electroencephalogram-monitored adult TLE patients at epilepsy specialist centers in two different countries, performed genome-wide PCR-based and RNA sequencing during the discovery phase and validated in a large cohort of samples (>300 samples) that included patients with psychogenic non-epileptic seizures. After profiling, validation of the discovery cohort and validation in the larger patient groups we identified miR-27a-3p, miR-328-3p and miR-654-3p with strong TLE biomarker potential. Plasma levels of these microRNAs were regulated in the same direction in plasma from epileptic mice, and furthermore were not different to healthy controls in patients with psychogenic non-epileptic seizures. The biomarker potential was extended by determining microRNA copy number in plasma and we demonstrate rapid detection of these microRNAs using an electrochemical RNA microfluidic disk as a prototype point-of-care device. Investigation of the molecular transport mechanism in plasma determined analysis of all three microRNAs within the exosome-enriched provided highest diagnostic accuracy while levels of Argonaute-bound miR-328-3p selectively increased in patient samples collected after seizures. In situ hybridization revealed the presence of miR-27a-3p and miR-328-3p within neurons in human brain and bioinformatics analysis predicted targets linked to growth factor signaling and apoptosis. Taken together, this study extends evidence for the biomarker potential of circulating microRNAs for epilepsy diagnosis and mechanistic links to underlying pathomechanisms.

Dataset Information

Transcriptomic and proteomic analysis of human brain tissue from epileptic and non-epileptic groups

Publications

A transcriptomic and proteomic analysis and comparison of human brain tissue from patients with and without epilepsy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets